Moderna (MRNA) earnings call transcript summary & sentiment
Last call Fri 31 Jul 2026
Our read on the 31 July 2026 earnings call
Overall tone: Neutral to modestly positive
Overall tone
Neutral to modestly positive
Executive Summary
Moderna reported second quarter 2026 revenue of $145 million, exceeding top-end company guidance, and reiterated full-year expectations of up to 10% revenue growth.
Core Signals
Revenue Growth & Demand: Q2 total revenue was $145 million, up 2% year-over-year and above guidance, led by a 60% U.S. and 40% international revenue split.
Bullish Signals
Reduced full-year 2026 cash cost guidance by $0.2 billion to $4.0 billion and increased projected ending cash balance to $4.7–$5.2 billion.
Risk Signals
Failed to hit early efficacy criteria in the Phase 3 norovirus study interim analysis, necessitating the enrollment of an additional trial cohort.
Q&A Signals
Repeated analyst topics: Analysts repeatedly pushed on the statistical design and read-through potential of the Imtysmoran Phase 3 melanoma interim analysis, as well as the cause of the norovirus trial extension.
Key Investor Debate
The primary debate among investors centers on whether commercial progress in seasonal flu and international partnerships can offset core COVID revenue declines while late-stage oncology and rare disease programs mature.
Analyst Takeaway
Management demonstrated notable expense discipline by delivering $0.2 billion in cash cost savings, providing vital cushion against softening U.S. COVID retail volumes.
Those are the opening lines. The full read covers the whole earnings transcript: every
bullish and bearish signal, what analysts pressed hardest on, and where management
answered vaguely — each with the quote behind it. Every line sourced.
Ask about Moderna's earnings, or other S&P 500 earnings calls
Ask across the corpus, instead of reading one call at a time. Scope it to Moderna, its
sector, or every name we cover — plain English, no operators — and answers come back
structured: a summary, the drivers, and a read on each company.
"What did Moderna say about margins, and did the framing change from last quarter?"
"Did Moderna's management walk back any full-year guidance, and how did they frame it?"
"Where did Moderna avoid answering on capital allocation?"
Sentiment analysis on any single earnings call, themes building across a sector, and search
across every company and quarter — each claim linked back to the passage it came from.